L. reuteri strains

The first strain of Lactobacillus reuteri (L. reuteri) for human use, L. reuteri DSM 17938, was isolated in 1990 from the breast milk of a Peruvian mother living in the Andes. The commercial name is L. reuteri Protectis. Other human strains used commercially are L. reuteri ATCC PTA 5289 and ATCC PTA 6475. L. reuteri ATCC PTA 5289 used in oral health products was isolated from the oral cavity of a Japanese woman with remarkable good dental status and L. reuteri ATCC PTA 6475 was isolated from breast milk in Finland.

To date the efficacy and safety of BioGaia’s different strains of L. reuteri have been documented in 163 studies in 14,000 people of all ages. Results have been published in 136 papers in scientific journals (September 2016). This makes it one of the most studied probiotics in the world. BioGaia’s commercial strains of L. reuteri are derived from breast milk and saliva in humans.

Dosage and colonisation 

Based on clinical data 100 million CFU/day has been chosen as a safe and efficacious dose of L. reuteri Protectis in man. Further, since L. reuteri colonisation is transient, dosing should be maintained to ensure adequate and stable L. reuteri levels in the gastrointestinal tract. Colonisation of L. reuteri Protectis has been studied throughout the entire human gastrointestinal tract using biopsies technique.

 

Probiotic strains and safety

BioGaia’s L. reuteri is one of the most scientifically well-documented probiotics with regard to both efficacy and safety, tested in 14,000 infants, children and adults.

BioGaia’s L. reuteri has been tested for host tolerance in term and infants, children, healthy adults and immune compromised adults. No serious adverse effects have been observed up to the maximum tested dosage of 10 billion CFU/day, meaning 1000 times the recommended daily dose.

L. reuteri is considered safe as it fulfils the following criteria:

  • Host specific origin
  • Named and classified according to correct taxonomy
  • Manufactured under controlled conditions to eliminate contamination with other microbes or substances
  • Safety is clearly evaluated and documented on target population
  • Harbors no toxin or transferrable antibiotic resistance genes

 

Read more about the Safety studies 

Crawling baby

The information on this part of the website is intended only for health care and business professionals. If you are not a health care or business professional and would like to learn more about the indications BioGaia works with, please visit our Expertise pages.

Please read terms & conditions before accepting. By clicking on the button “I acknowledge and accept” you confirm that you are a healthcare or business professional and have read and understood this disclaimer including the terms and conditions.